MICHAËL HANANJA MEEL, MD, PhD

POSTDOCTORAL RESEARCHER &
RESIDENT PEDIATRIC NEURO-ONCOLOGY

PERSONAL DETAILS

July 7th, 1989 (Age 35)

+31 648924500

m.h.meel@prinsesmaximacentrum.nl

Heidelberglaan 25,
3584CS Utrecht
The Netherlands

EXPERTISE

- Pediatric oncology
- Neuro-oncology
- Translational research
- Preclinical disease models
- Preclinical therapy development
- Tumor immunology
- Blood-brain barrier

LANGUAGES

- English (Fluent)
- Dutch (Native)
- Spanish (Fluent)
- German (Basic)
- French (Basic)

WORK EXPERIENCE

POSTDOCTORAL RESEARCH FELLOW
2020 - PRESENT

Princess Máxima Center for Pediatric Oncology
Utrecht, The Netherlands

Preclinical research for the development of representative disease models and treatment strategies for diffuse midline glioma. Funded by personal fellowship grant for clinician scientists from the Princess Máxima Center.

RESIDENT IN PEDIATRICS
2021 - PRESENT

Wilhelmina Children's Hospital &
Princess Máxima Center for Pediatric Oncology
Utrecht, The Netherlands

RESIDENT IN PEDIATRIC ONCOLOGY & POSTDOCTORAL FELLOW
2024

Hospital Universitari i Politècnic La Fe/Instituto de Investigación Sanitaria La Fe, Valencia, Spain

RESIDENT IN PEDIATRIC ONCOLOGY
2019-2020

Princess Máxima Center for Pediatric Oncology
Utrecht, The Netherlands

PHD STUDENT PEDIATRIC ONCOLOGY
2014-2019

Amsterdam University Medical Centers
Amsterdam, The Netherlands

Preclinical therapy development for aggressive pediatric brain tumors. Awarded with the Tom Voûte Young Investigator Award (2018) and *cum laude* designation of doctoral thesis.

HIGHLIGHTED GRANTS & PROJECTS

FUNDACIÓN MARTIN
2025-2027

Investigation of the tumor immune microenvironment in diffuse midline glioma

Role: PI

QUEEN WILHELMINA FOUNDATION
2023-2027

Towards immune-based therapies for diffuse midline glioma: exposing the immunomodulatory effects of ONC201.

Role: co-PI

DUTCH CHILDREN CANCER FREE FOUNDATION
2021-2025

Enabling preclinical immunotherapeutic studies for pediatric diffuse midline glioma

Role: co-PI